These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31689133)

  • 41. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
    Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis.
    Freeman EE; McCann NC; Semeere A; Reddy KP; Laker-Oketta M; Byakwaga H; Pei PP; Hajny Fernandez ME; Kiprono S; Busakhala N; Martin JN; Maurer T; Bassett IV; Freedberg KA; Hyle EP
    Lancet Glob Health; 2022 Aug; 10(8):e1179-e1188. PubMed ID: 35839816
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
    PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa.
    Berry KM; Rodriguez CA; Berhanu RH; Ismail N; Mvusi L; Long L; Evans D
    BMC Public Health; 2019 Jul; 19(1):973. PubMed ID: 31331311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa.
    Floyd K; Wilkinson D; Gilks C
    BMJ; 1997 Nov; 315(7120):1407-11. PubMed ID: 9418087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
    HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD; Holtgrave DR; Layde PM
    Prev Med; 2000 Jan; 30(1):64-9. PubMed ID: 10642461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens.
    Zwerling A; Gomez GB; Pennington J; Cobelens F; Vassall A; Dowdy DW
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):257-60. PubMed ID: 26792481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study.
    Salazar-Austin N; Hoffmann J; Cohn S; Mashabela F; Waja Z; Lala S; Hoffmann C; Dooley KE; Chaisson RE; Martinson N;
    Clin Infect Dis; 2018 Mar; 66(6):921-929. PubMed ID: 29028970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.